Venture Capital

Novo infuses cash into 4 biotechs, adding to their arsenal for the superbugs battle to come

A year after Novo Holdings launched a $165 million fund to fill what it sees as an early-stage funding gap in research addressing the growing threat of antimicrobial resistance, it’s offering a review of four investments Novo has made totaling $20 million.

AstraZeneca-backed Entasis Therapeutics, Lund University spinout Minervax and UK-based Procarta Biosystems were selected alongside Polyphor, a Swiss biotech that previously announced Novo’s backing of its outer membrane protein targeting antibiotics (OMPTA) programs.

Aleks Engel

These four companies stood out among “100 high-quality proposals targeting the deadliest resistant pathogens on the planet,” said Aleks Engel, director of the REPAIR Impact Fund, in a statement.

Entasis claims the largest bet in the cohort at $10 million, which formed part of its IPO $ETTX in September. Run by survivors from an antibiotics division that once employed 175 people working for AstraZeneca, Entasis is developing drugs to block a common bacterial resistance via b-lactamase enzymes, and its preclinical pipeline also features non β-lactam PBP inhibitors targeting multi-resistant Pseudomonas aeruginosa infections.

Minervax bagged $4 million for its prophylactic vaccine against Group B Streptococcus — a common bacterium that can wreak havoc for newborns and cause stillbirths or preterm deliveries.

Novo also invested $1.7 million in Procarta’s nanoparticle approach — targeting bacterial transcription — while Polyphor got $6.8 million, with $4.7 million worth of milestones on the line.

While superbugs pose a serious threat to the world’s population, claiming more than 700,000 lives each year by some estimates, the market still offers little encouragement for new programs. Identifying a lack of money supporting the period from lead optimization up to Phase I data, Novo unveiled the trans-Atlantic fund in February, 2018 to complement other funding sources such as research grants offered by the $500 million-plus, public/private CARB-X partnership.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->